Terence R Flotte

发表

The Target's the Thing.

Terence R Flotte, 2016, Human gene therapy.

Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults.

Terence R Flotte, T. Flotte, B. Byrne, 2004, Human gene therapy.

Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material.

Terence R Flotte, Hiroaki Mizukami, Mauro Giacca, 2010, Human gene therapy.

Recombinant Adeno-Associated Virus Vector Genomes Take the Form of Long-Lived, Transcriptionally Competent Episomes in Human Muscle.

Philip R. Johnson, Terence R Flotte, Philip R Johnson, 2016, Human gene therapy.

Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here?

Terence R Flotte, T. Flotte, Allison M Keeler, 2019, Annual review of virology.

Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics

Edwin M Stone, Terence R Flotte, Alexander Sumaroka, 2008, Proceedings of the National Academy of Sciences.

Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults.

Sihong Song, Terence R Flotte, T. Conlon, 2006, Human gene therapy.

A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies.

Terence R Flotte, Phyllis Gardner, T. Flotte, 2002, Human gene therapy.

Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study.

Terence R Flotte, Suzanne Beck, T. Flotte, 2003, Human gene therapy.

Improved method of recombinant AAV2 delivery for systemic targeted gene therapy.

Jon Dobson, Sihong Song, Terence R Flotte, 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

In Vivo Genome Editing Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency.

Zhiping Weng, Hao Yin, Terence R Flotte, 2018, Human gene therapy.